Table 2.
First line trials of 2 nd generation TKI in EGFR mutated patients
| N | OR% | mPFS (mo) | mOS (mo) | |
|---|---|---|---|---|
| Dacomitinib | ||||
| Phase II trial30 | 92 | 74 | 17 | NR |
| Afatinib | ||||
| LUX LUNG II trial 34 | ||||
| All EGFR mutations | 129 | 61 | 10.1 | 24.8 |
| Exon 19–21 mutations | 106 | 66 | 13.7 | 38.7 |
| LUX LUNG III trial 35 | ||||
| All EGFR mutations | ||||
| Afatinib | 230 | 56 | 11.1 | NR |
| Cis/Gem | 115 | 23 | 6.9 | NR |
| Exon 19–21 mutations | ||||
| Afatinib | 204 | - | 13.6 | NR |
| Cis/Gem | 104 | - | 6.9 | NR |
| LUX LUNG VI trial 39 | ||||
| All EGFR mutations | ||||
| Afatinib | 242 | 66.9 | 11.1 | |
| Cis/Gem | 122 | 23 | 5.6 | |
| XL647 | ||||
| Phase II trial53 | ||||
| All EGFR mutations | 41 | 20 | 5.3 | 19 |
| Exon 19–21 mutations | 14 | 57 | 9.3 | NR |